Related Experiment Video

Updated: Aug 11, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor

R Kuefer1, M Autenrieth, K Herkommer

  • 1Urologische Universitätsklinik und Poliklinik, Universität Ulm.

Der Urologe. Ausg. A
|February 9, 2006
PubMed

Insights

Limited treatment options exist for metastatic renal cell cancer (RCC) after cytokine therapy. Targeting the vascular endothelial growth factor (VEGF) pathway shows promise for new systemic therapies in RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell cancer (RCC) presents limited therapeutic avenues post-cytokine treatment.
  • The von Hippel-Lindau gene's loss leads to vascular endothelial growth factor (VEGF) pathway upregulation, presenting a therapeutic target.
  • A need exists for novel systemic therapies in advanced RCC.

Purpose of the Study:

  • To review the molecular basis of VEGF pathway dysregulation in metastatic RCC.
  • To provide an overview of emerging anti-VEGF agents in clinical trials for metastatic RCC.
  • To discuss the current status and future directions of VEGF-targeted therapies in RCC.

Main Methods:

  • Literature review of preclinical and clinical studies on VEGF pathway inhibitors in RCC.
  • Analysis of molecular mechanisms driving VEGF pathway activation in RCC.
  • Summary of data from early-phase clinical trials of novel agents targeting VEGF.

Main Results:

  • Several therapeutic agents inhibiting the VEGF pathway at different levels have been developed.
  • Early clinical trial results for these agents in metastatic RCC are promising.
  • The VEGF pathway is a validated target for molecular-based therapy in RCC.

Conclusions:

  • VEGF pathway inhibitors represent a promising new class of drugs for metastatic RCC.
  • Further research is needed to determine optimal dosing, scheduling, and combination strategies.
  • Long-term efficacy and safety data are required to fully establish the role of these agents in RCC treatment.

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...